Aclaris Therapeutics to Present at Upcoming Investor Conferences
01 sept. 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
07 août 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
•First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis •First Subject Dosed in Phase 2a Trial...
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
07 juil. 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for...
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
17 juin 2020 07h01 HE
|
Aclaris Therapeutics, Inc.
FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19Aclaris Supports Investigator-Initiated Clinical Trial Sponsored by the University of Kansas Medical CenterATI-450 Inhibits...
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
03 juin 2020 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for...
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
26 mai 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that...
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
07 mai 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
Projected Cash Runway into the First Quarter of 2022Borrowed $11 Million from Term Loan Facility WAYNE, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a...
Aclaris Therapeutics Secures $11 Million Term Loan Facility
31 mars 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., March 31, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
25 févr. 2020 16h01 HE
|
Aclaris Therapeutics, Inc.
Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 InhibitorProjected Cash Runway into the Third Quarter of 2021Management to...
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
19 févr. 2020 17h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will...